Consensus Exelixis, Inc.

Stocks

EXEL

US30161Q1040

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-11-12 EST			5-day change	1st Jan Change
69.84 ^USD	-1.22%		-4.00%	+59.34%

11-11	Exelixis, Inc. Presents at Stifel 2026 Healthcare Conference 2026, Nov-11-2026 01:20 PM
11-10	Exelixis, Inc. Presents at 3rd Annual Guggenheim Healthcare Innovation Conference, Nov-10-2026 09:30 AM

Evolution of the Average Target: Exelixis, Inc.

Evolution of the Target Price: Exelixis, Inc.

Changes in Analyst Recommendations: Exelixis, Inc.

0ce9a798ffd0bebdee04.k_t5KFxmQmEhAPYWe09bgGdWFQ4y-psgMC08Nb7zCSI.oqxLQ283OwZQX7JlDBsa5EoEXzZjmMtPal1sY-6kc1bJzRRxMytxERRDlQ~108bfe8f1ebf8e36677173fda64fea16

Analysts' recommendations: Exelixis, Inc.

10-30	RBC Raises Price Target on Exelixis to $58 From $51, Keeps Sector Perform Rating	MT
10-30	Analyst recommendations: GE Vernova, Intel, Reddit, Caterpillar, Crocs…
10-09	Exelixis' Zanzalintinib Clinical Trials for Cancer Highly Likely to Succeed, RBC Says	MT
10-09	RBC Raises Price Target on Exelixis to $51 From $45, Keeps Sector Perform Rating	MT
10-08	RBC Trims Price Target on Exelixis to $45 From $46, Keeps Sector Perform Rating	MT
07-23	Analyst recommendations: Duke Energy, JPMorgan Chase, M&T Bank, Super Micro, Texas Instruments…
07-13	Analyst recommendations: Biogen, Deckers Outdoor, Fortinet, Marathon Petroleum, UnitedHealth…
07-07	RBC Capital Adjusts Exelixis Price Target to $46 From $43, Maintains Sector Perform Rating	MT
07-02	Exelixis Faces Balanced Risk-Reward Ahead of Key Catalysts, UBS Says	MT
07-02	UBS Adjusts Price Target on Exelixis to $52 From $43, Maintains Neutral Rating	MT
07-02	Analyst recommendations: Adobe, AA, Nike, Exelixis…
05-06	Exelixis Seen Trading Steady on Modest Drug Growth, RBC Says	MT
03-02	RBC Lowers Price Target on Exelixis to $43 From $46, Keeps Sector Perform Rating	MT
02-11	RBC Raises Price Target on Exelixis to $46 From $45, Keeps Sector Perform Rating	MT
02-02	Morgan Stanley Lifts Price Target on Exelixis to $49 From $48, Keeps Overweight Rating	MT
01-14	Truist Securities Adjusts Price Target on Exelixis to $51 From $49, Maintains Buy Rating	MT
01-08	Exelixis Shares Fall After Downgrade From Morgan Stanley	MT
01-08	Morgan Stanley Downgrades Exelixis to Equalweight, Price Target is $48	MT
01-05	Exelixis Faces Limited High-Impact Catalysts, BofA Says	MT
01-05	BofA Securities Downgrades Exelixis to Underperform From Neutral, Adjusts Price Target to $41 From $43	MT
11-06	UBS Adjusts Price Target on Exelixis to $40 From $35, Maintains Neutral Rating	MT
11-05	Morgan Stanley Lifts Price Target on Exelixis to $45 From $44, Keeps Overweight Rating	MT
11-03	Exelixis Shares Fall After Guggenheim Downgrade	MT
11-03	Guggenheim Downgrades Exelixis to Neutral From Buy	MT
25-10-21	Exelixis Shares Rise After Leerink Partners Upgrade	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	EXELIXIS, INC.					-12.91%
	WUXI APPTEC CO., LTD.					+36.07%
	ARGENX SE					+15.3%
	LONZA GROUP AG					+7.92%
	BEONE MEDICINES AG					+10.05%
	IQVIA HOLDINGS INC.					+13.61%
	REVOLUTION MEDICINES, INC.					+52.1%
	CELLTRION, INC.					+33.03%
	GENMAB A/S					+13.92%
	INSMED INCORPORATED					+60.81%
	Average					+22.99%
	Weighted average by Cap.					+23.23%